U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07437105) titled 'Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants' on Feb. 20.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Cystic Fibrosis
Intervention:
DRUG: VX-272
Suspension for Oral Administration.
DRUG: Placebo
Suspension for Oral Administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vertex Pharmaceuticals Incorporated
Published by HT Digital Content Services with permission from Health Daily Digest....